Brokerages Set $42.00 Price Target for Covetrus Inc (CVET)

Covetrus Inc (NASDAQ:CVET) has earned an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.

Analysts have set a 12 month consensus price target of $42.00 for the company and are anticipating that the company will post $0.17 earnings per share for the current quarter, according to Zacks. Zacks has also given Covetrus an industry rank of 52 out of 255 based on the ratings given to related companies.

A number of research analysts have weighed in on CVET shares. William Blair started coverage on Covetrus in a report on Tuesday, February 12th. They issued an “outperform” rating on the stock. Raymond James started coverage on Covetrus in a report on Wednesday, February 27th. They issued an “outperform” rating and a $45.00 target price on the stock. Svb Leerink reissued an “outperform” rating on shares of Covetrus in a report on Wednesday, March 20th. Finally, Credit Suisse Group started coverage on Covetrus in a report on Thursday. They issued a “neutral” rating and a $35.00 target price on the stock.

CVET stock traded up $0.21 during trading on Thursday, reaching $32.44. The stock had a trading volume of 36,292 shares, compared to its average volume of 1,052,424. Covetrus has a 52 week low of $30.71 and a 52 week high of $43.83.

Covetrus Company Profile

Covetrus, Inc operates as an animal-health technology and services company. The company engages in the distribution of pharmaceuticals, nutrition products, consumable products, diagnostic tests, small and large equipment, laboratory products, surgical products, and others. It also develops, sells, and distributes practice management software systems and computer hardware for animal health customers, as well as offers software support, data driven applications, training and education, client communication services, and value-added services.

See Also: Retained Earnings

Get a free copy of the Zacks research report on Covetrus (CVET)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with MarketBeat.com's FREE daily email newsletter.